Pandemic Darlings The pandemic economy, in original documents
Home Form 4: Emergent BioSolutions Inc. (EBS), Saran Atul, transaction 08/07/2020Search ⌕

Form 4: Emergent BioSolutions Inc. (EBS), Saran Atul, transaction 08/07/2020

Summary

A Form 4 for Emergent BioSolutions Inc. [EBS] reports a transaction by SARAN ATUL, an officer whose title is given as EVP, Corp Dev, GC & Secretary. On August 7, 2020, 1,303 shares of common stock were disposed of under transaction code F at a price of $126.96, leaving 39,496 shares owned directly. The explanation of responses says the common stock line consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated. The form is signed /s/ S. Scott Lieberman, Attorney-in-fact, on August 11, 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Cite this document

“Form 4: Emergent BioSolutions Inc. (EBS), Saran Atul, transaction 08/07/2020.” Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-ebs-4-filed2020-08-11-0001367644-20-000132-c627c1efa3/, SHA-256 c484fe21ada37e73b8c18822ab36d69f478eeb02b289ac8afcb7569212c61dc4.

Full text

SEC Form 4

FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person * SARAN ATUL (Last) (First) (Middle) 400 PROFESSIONAL DRIVE SUITE 400 (Street) GAITHERSBURG MD 20879 (City) (State) (Zip) | SARAN ATUL | (Last) | (First) | (Middle) | 400 PROFESSIONAL DRIVE | SUITE 400 | GAITHERSBURG | MD | 20879 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol Emergent BioSolutions Inc. [ EBS ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) EVP, Corp Dev, GC & Secretary | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | EVP, Corp Dev, GC & Secretary
3. Date of Earliest Transaction
 (Month/Day/Year) 08/07/2020
4. If Amendment, Date of Original Filed
 (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr.
 3) | 2. Transaction Date
 (Month/Day/Year) | 2A. Deemed Execution Date, if any
 (Month/Day/Year) | 3. Transaction Code (Instr.
 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr.
 3, 4 and 5) | 5.
 Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 7. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | Amount | (A) or (D) | Price
Common Stock (1) | 08/07/2020 | F | 1,303 | D | $ 126.96 | 39,496 | D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr.
 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date
 (Month/Day/Year) | 3A. Deemed Execution Date, if any
 (Month/Day/Year) | 4. Transaction Code (Instr.
 8) | 5.
 Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr.
 3, 4 and 5) | 6. Date Exercisable and Expiration Date
 (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr.
 3 and 4) | 8. Price of Derivative Security (Instr.
 5) | 9.
 Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr.
 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr.
 4) | 11. Nature of Indirect Beneficial Ownership (Instr.
 4)
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares
Explanation of Responses:
1. Consists of restricted stock units granted under the Company's Stock Incentive Plan, as amended and restated.
Remarks:
/s/ S. Scott Lieberman, Attorney-in-fact | 08/11/2020
** Signature of Reporting Person | Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction
 4

 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

File and source

File
SEC_EBS_4_filed2020-08-11_0001367644-20-000132.xml
Size
15,023 bytes
SHA-256
c484fe21ada37e73b8c18822ab36d69f478eeb02b289ac8afcb7569212c61dc4
Our copy
SEC_EBS_4_filed2020-08-11_0001367644-20-000132.xml
Original
www.sec.gov
Back to top